The IAEA-ACC study compared accelerated radiotherapy with standard radiotherapy in a multicenter trial conducted in developing countries. Advantages were most notable in patients with early-stage disease, which may limit the utility of this therapy. In countries where resources are limited, however, this strategy may be a cost-effective approach to improving outcomes in patients with head and neck cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Overgaard, J. et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol. 11, 553–560 (2010).
Overgaard, J. et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362, 933–940 (2003).
Zackrisson, B., Mercke, C., Strander, H., Wennerberg, J. & Cavallin-Ståhl, E. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol. 42, 443–461 (2003).
Overgaard, J. et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother. Oncol. 46, 135–146 (1998).
Fu, K. K. et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys. 48, 7–16 (2000).
Bourhis, J. et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368, 843–854 (2006).
Posner, M. R. et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 357, 1705–1715 (2007).
Pignon, J. P., le Maître, A., Maillard, E., Bourhis, J. & MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92, 4–14 (2009).
Bonner, J. A. et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21–28 (2010).
Brizel, D. M. et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 338, 1798–1804 (1998).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Brockstein, B., Vokes, E. Accelerated radiotherapy for HNSCC in developing countries. Nat Rev Clin Oncol 7, 616–618 (2010). https://doi.org/10.1038/nrclinonc.2010.159
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.159
